| MANNKIND CORP. NEW DL-,01 |
| USA |
| Gesundheit |
| US56400P7069 / A2DMZL |
| NNFN (Frankfurt) / MNKD (NASDAQ) |
| FRA:NNFN, ETR:NNFN, NNFN:GR, NASDAQ:MNKD |
| - |
| https://mannkindcorp.com/ |
|
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapies and devices for patients with cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid o..
>Volltext.. |
| 677.96 Mio. EUR |
| 935 Mio. EUR |
| 302.31 Mio. EUR |
| 57.63 Mio. EUR |
| 5.08 Mio. EUR |
| 0.02 EUR |
| 410.1 Mio. EUR |
| 64.87 Mio. EUR |
| 15.81 Mio. EUR |
| 1 |
| 7.73% |
| -81.27% |
| - |
| - |
| - |
| MANNKIND |
| 04.04.26 |